IL171843A - TRIAZOLE DERIVATIVES AS FACTOR Xa INHIBITORS - Google Patents

TRIAZOLE DERIVATIVES AS FACTOR Xa INHIBITORS

Info

Publication number
IL171843A
IL171843A IL171843A IL17184305A IL171843A IL 171843 A IL171843 A IL 171843A IL 171843 A IL171843 A IL 171843A IL 17184305 A IL17184305 A IL 17184305A IL 171843 A IL171843 A IL 171843A
Authority
IL
Israel
Prior art keywords
factor
compounds
formulae
chem
factor viia
Prior art date
Application number
IL171843A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of IL171843A publication Critical patent/IL171843A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL171843A 2003-05-19 2005-11-08 TRIAZOLE DERIVATIVES AS FACTOR Xa INHIBITORS IL171843A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011309A EP1479679A1 (en) 2003-05-19 2003-05-19 Triazole-derivatives as factor Xa inhibitors
PCT/EP2004/004752 WO2004101555A1 (en) 2003-05-19 2004-05-05 TRIAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (1)

Publication Number Publication Date
IL171843A true IL171843A (en) 2010-12-30

Family

ID=33040956

Family Applications (1)

Application Number Title Priority Date Filing Date
IL171843A IL171843A (en) 2003-05-19 2005-11-08 TRIAZOLE DERIVATIVES AS FACTOR Xa INHIBITORS

Country Status (12)

Country Link
EP (2) EP1479679A1 (enExample)
JP (1) JP4608495B2 (enExample)
AT (1) ATE394396T1 (enExample)
AU (1) AU2004238498B2 (enExample)
BR (1) BRPI0410763A (enExample)
CA (1) CA2526082C (enExample)
DE (1) DE602004013577D1 (enExample)
IL (1) IL171843A (enExample)
MX (1) MXPA05012058A (enExample)
PE (1) PE20050154A1 (enExample)
TW (1) TW200503694A (enExample)
WO (1) WO2004101555A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
KR101362024B1 (ko) * 2006-03-24 2014-02-11 에자이 알앤드디 매니지먼트 가부시키가이샤 트리아졸론 유도체
SG187396A1 (en) * 2007-07-19 2013-02-28 Lundbeck & Co As H 5-membered heterocyclic amides and related compounds
US7807690B2 (en) 2007-09-21 2010-10-05 Eisai R&D Management Co., Ltd. 2,3-dihydro-iminoisoindole derivatives
RU2017144535A (ru) 2010-03-30 2019-02-18 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
BR112015023214A8 (pt) * 2013-03-15 2019-12-24 Verseon Corp composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica
PL2968297T3 (pl) 2013-03-15 2019-04-30 Verseon Corp Wielopodstawione związki aromatyczne jako inhibitory protezy serynowej
CA2907111C (en) 2013-03-15 2023-10-24 Joel Moore Sgc stimulators
EP3194369A4 (en) 2014-09-17 2018-02-28 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
CA2977993A1 (en) 2015-02-27 2016-09-01 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
US11724997B2 (en) 2018-03-01 2023-08-15 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
CA2314401A1 (en) * 1997-12-22 1999-07-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
WO2001032628A1 (en) * 1999-11-03 2001-05-10 Bristol-Myers Squibb Pharma Company Cyano compounds as factor xa inhibitors
WO2002000651A2 (en) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors

Also Published As

Publication number Publication date
TW200503694A (en) 2005-02-01
JP4608495B2 (ja) 2011-01-12
ATE394396T1 (de) 2008-05-15
EP1628971B1 (en) 2008-05-07
WO2004101555A1 (en) 2004-11-25
EP1628971A1 (en) 2006-03-01
EP1479679A1 (en) 2004-11-24
CA2526082C (en) 2012-07-24
AU2004238498A1 (en) 2004-11-25
AU2004238498B2 (en) 2010-07-22
JP2006528941A (ja) 2006-12-28
CA2526082A1 (en) 2004-11-25
DE602004013577D1 (de) 2008-06-19
MXPA05012058A (es) 2006-06-23
PE20050154A1 (es) 2005-04-29
BRPI0410763A (pt) 2006-08-01

Similar Documents

Publication Publication Date Title
ATE429432T1 (de) Indazolderivate als faktor xa-inhibitoren
DE602004028367D1 (de) Neue indolderivate als faktor xa-inhibitoren
WO2003044014A8 (en) Indole-2-carboxamides as factor xa inhibitors
SI1349847T1 (en) Oxybenzamides derivatives as factor xa inhibitors
TW200505914A (en) Pyrazole-derivatives as factor Xa inhibitors
WO2005085239A3 (en) PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS
PL359584A1 (en) Factor viia inhibitory (thio)urea derivatives, their preparation and their use
AU2002325238A1 (en) Urea derivatives with antiproteolytic activity
YU29702A (sh) N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih obuhvataju
IL171843A (en) TRIAZOLE DERIVATIVES AS FACTOR Xa INHIBITORS
WO2004050636A3 (en) IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
TW200503696A (en) Benzimidazole-derivatives as factor Xa inhibitors
UA86767C2 (ru) АЗАИНДОЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ ФАКТОРА Ха
TW200716620A (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors
JO2467B1 (en) New indole derivatives as an inhibitor of Xa

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees